Blood cancers

Novel agents for follicular lymphoma: Who needs them?

The very good outcomes for most patients with follicular lymphoma leave only a small proportion who stand to benefit from novel treatments, an international expert has told the conference. Professor Jonathan Friedberg, Director of the James P Wilmot Cancer Institute in Rochester, New York, told delegates follicular lymphoma is the second most common type of ...

Already a member?

Login to keep reading.

© 2021 the limbic